Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 12/20 | 0.51 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.51 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.51 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.51 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.51 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.51 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.51 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4079566 | 0.98 | SIGMAR1 (0.53) | RAPGEF4SIGMAR1GRIN2DGRIN3BGRIN1 | |
| Water SCHEMBL27001752 | 0.98 | RAPGEF4 (0.51) | RAPGEF4SIGMAR1GRIN2DGRIN3BGRIN1 | |
| Bromide SCHEMBL20984749 | 0.98 | RAPGEF4 (0.51) | RAPGEF4SIGMAR1GRIN2DGRIN3BGRIN1 | |
| Water SCHEMBL29861880 | 0.98 | RAPGEF4 (0.51) | RAPGEF4SIGMAR1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL27273814 | 0.98 | RAPGEF4 (0.51) | RAPGEF4SIGMAR1GRIN2DGRIN3BGRIN1 | |
| Oxalic Acid SCHEMBL20984481 | 0.89 | SMN1; SMN2 (0.51) | RAPGEF4SIGMAR1GRIN2DGRIN3BGRIN1 | |
| Phosphoric Acid SCHEMBL20984605 | 0.89 | SMN1; SMN2 (0.48) | RAPGEF4SIGMAR1GRIN2DGRIN3BGRIN1 | |
| Sulfuric Acid SCHEMBL20984390 | 0.89 | SIGMAR1 (0.48) | RAPGEF4SIGMAR1GRIN2DGRIN3BGRIN1 | |
| Nitric Acid SCHEMBL20984778 | 0.86 | GAA (0.52) | RAPGEF4SIGMAR1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL11585925 | 0.83 | GRIN2D (0.54) | RAPGEF4SIGMAR1GRIN2DGRIN3BGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107674028-A | A kind of synthetic method of pyrazoline ketone compounds | 天津瑞岭化工有限公司 | 2018-02-09 | — | — | CN | claimed |
| CN-107652237-A | A kind of synthetic method of pyrazolone and its derivative | 天津瑞岭化工有限公司 | 2018-02-02 | — | — | CN | claimed |
| WO-2022040157-A1 | BORON CONTAINING COMPOUNDS AND THEIR USES | 5METIS, INC. (US) | 2022-02-24 | — | — | WO | disclosed |
| CN-107663161-A | A kind of continuous stream synthesis technique of phenylhydrazine salt and substituted benzene hydrazonium salt | 上海惠和化德生物科技有限公司 | 2018-02-06 | — | — | CN | disclosed |
| US-9708295-B2 | Substituted 2-aminopyridine protein kinase inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2017-07-18 | — | — | US | disclosed |
| US-9562019-B2 | Substituted pyridazines as EGFR and/or KRAS inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2017-02-07 | — | — | US | disclosed |
| US-20160002205-A1 | SUBSTITUTED 2-AMINOPYRIDINE PROTEIN KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD (CN) | 2016-01-07 | — | — | US | disclosed |
| US-9176406-B2 | Toner, development agent, image forming apparatus, and process cartridge | RICOH COMPANY, LTD. (JP) | 2015-11-03 | — | — | US | disclosed |
| EP-2099770-B1 | PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS | SLOAN KETTERING INST CANCER (US) | 2015-06-10 | — | — | EP | disclosed |
| US-8680150-B2 | Small molecule hematopoietic growth factor mimetic compounds that activate hematopoietic growth factor receptors | LIGAND PHARMACEUTICALS, INC. (US) | 2014-03-25 | — | — | US | disclosed |
| US-20140051019-A1 | TONER, DEVELOPMENT AGENT, IMAGE FORMING APPARATUS, AND PROCESS CARTRIDGE | RICOH COMPANY, LTD. (JP) | 2014-02-20 | — | — | US | disclosed |
| CN-1016398-B | The pollen that contains pyrazole derivatives generates composite inhibiting | ELLI LILLY & CO (US) | 1992-04-29 | — | — | CN | disclosed |
| EP-0177242-B1 | POLLEN FORMATION INHIBITING PYRAZOLES | ELI LILLY AND COMPANY (US) | 1990-01-03 | — | — | EP | disclosed |
| US-4775409-A | PREVENTING POLLEN FORMATION | ELI LILLY AND COMPANY (US) | 1988-10-04 | — | — | US | disclosed |
| US-4666504-A | HYBRIDS | ELI LILLY AND COMPANY (US) | 1987-05-19 | — | — | US | disclosed |
| CN-85107078-A | The pollen that contains pyridine derivate generates composite inhibiting | — | 1987-04-01 | — | — | CN | disclosed |
| EP-0177242-A2 | Pollen formation inhibiting pyrazoles | ELI LILLY AND COMPANY (US) | 1986-04-09 | — | — | EP | disclosed |
| US-4226774-A | Carbazole melonates | HOFFMANN-LA ROCHE INC. (US) | 1980-10-07 | — | — | US | disclosed |
| US-4193923-A | Tetrahydro 2-carbazolyl methyl malonate derivatives | HOFFMANN-LA ROCHE INC. (US) | 1980-03-18 | — | — | US | disclosed |
| US-4158007-A | Carbazole methyl malonates | HOFFMANN-LA ROCHE INC. (US) | 1979-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002205-A1 | SUBSTITUTED 2-AMINOPYRIDINE PROTEIN KINASE INHIBITOR | PACSIN2, MAPKAPK2, PRKCA | RAPGEF4 603/4885SIGMAR1 2827/4885GRIN2D 574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.